Physician profile
Robert W Cox
NPI 1164480026
$1,675.49
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,380 · 2020: $295.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $354.38 | 2019-2020 | |
| Amgen INC. | $338.91 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $154.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $152.44 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $145.04 | 2019-2020 | |
| Astellas Pharma US INC | $112.16 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.28 | 2019-2020 | |
| Lilly USA, LLC | $50.00 | 2019-2020 | |
| Pfizer INC. | $47.80 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $41.54 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.23 | 2019-2020 | |
| Amarin Pharma, INC. | $36.96 | 2019 | |
| Abbvie INC. | $32.39 | 2019-2020 | |
| Hikma Pharmaceuticals USA | $25.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $17.29 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $15.60 | 2019 | |
| Glaxosmithkline, LLC. | $14.04 | 2019 | |
| Daiichi Sankyo INC. | $12.67 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.